Pre-Exposure Prophylaxis and Treatment with Tixagevimab/Cilgavimab for COVID-19 among Immunocompromised Pediatric Patients

Pre-Exposure Prophylaxis and Treatment with Tixagevimab/Cilgavimab for COVID-19 among Immunocompromised Pediatric Patients

<b>Background:</b> Patients treated with hemato-oncological malignancies (HO) or undergoing cellular therapies such as hematopoietic stem cell transplantation (HSCT) or chimeric antigen receptor T cells (CAR-T) were significantly affected by severe acute respiratory syndrome coronavirus...

Full description

Bibliographic Details
Main Authors: Jowita Frączkiewicz, Katarzyna Pawińska-Wąsikowska, Katarzyna Szymbor, Walentyna Balwierz, Szymon Skoczeń, Krzysztof Czyżewski, Sylwia Kołtan, Jan Styczyński, Anna Małecka, Ninela Irga-Jaworska, Joanna Trelińska, Wojciech Młynarski, Olga Zając-Spychała, Agnieszka Sobkowiak-Sobierajska, Katarzyna Derwich, Wioletta Bal, Radosław Chaber, Agnieszka Książek, Tomasz Szczepański, Joanna Zawitkowska, Katarzyna Drabko, Agnieszka Chodała-Grzywacz, Grażyna Karolczyk, Christopher Kobierzycki, Krzysztof Kałwak
Format: Article
Language:English
Published: MDPI AG 2024-03-01
Series:Journal of Clinical Medicine
Subjects:
COVID-19
immunocompromised patients
monoclonal antibodies
tixagevimab
cilgavimab
evusheld
Online Access:https://www.mdpi.com/2077-0383/13/7/2029

Internet

https://www.mdpi.com/2077-0383/13/7/2029

Similar Items